Overview

A Phase III Study To Evaluate the Efficacy And Safety Of SHR-1918 In Participants With Hypertriglyceridemia

Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypertriglyceridemia. The efficacy and safety of SHR-1918 will be evaluated after 24-weeks and 48-weeks treatment.
Phase:
PHASE3
Details
Lead Sponsor:
Beijing Suncadia Pharmaceuticals Co., Ltd